The Th2/Th17 pathway in asthma and the relevant clinical significance
More details
Hide details
Asthma Clinic, Pulmonary Department, Aristotle University of Thessaloniki, George Papanikolaou Hospital, Exochi
Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences , Aristotle University of Thessaloniki , Thessaloniki, Greece
Corresponding author
Despoina Papakosta   

Pneumonology Lung Immunology, Pulmonary Department Aristotle University of Thessaloniki, Greece
Pneumon 2018;31(3):174-182
Asthma is a heterogeneous chronic disease of the airways, characterized by different phenotypes. The principal pathophysiological pathway appears to be Th2 dependent eosinophilic inflammation mainly produced by T helper 2 (Th2) cells. More recently epithelial innate lymphoid cells (ILC2) cell shave been implicated as another source of Th2 cytokines leading to bronchial eosinophilia without previous allergen sensitization. Another pathogenic pathway is the non-Th2 type, mediated by Th1 and especially Th17 lymphocytes, responsible for neutrophilicin flammation. Furthermore, recent studies have associated Th-17 cells with allergic inflammation and eosinophilic asthma. Ongoing clinical trials are expected to further elucidate the role of different cells in the evolution of asthmatic inflammation and also the role of established or novel potential biomarkers in routine clinical practice aiming to maximize drug efficacy in asthmatics. In the present review, we summarize the above mentioned mechanisms focusing on T-helper cell subset plasticity which led to the identification of dual positive Th2/Th17 inflammation.
From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2015.
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368(9537):804-13.
Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. The Journal of Allergy and Clinical Immunology 2011;127:355-60.
Afshar R, Medoff BD, Luster AD. Allergic asthma: a tale of many T cells. Clin Exp Allergy 2008;38:1847-57.
Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology 2007;8:967-74.
Yu S, Kim HY, Chang YJ, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. The Journal of Allergy and Clinical Immunology 2014;133:943-50; quiz 51. Epub 2014/04/01.
Spits H, Artis D, Colonna M, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nature Reviews Immunology 2013;13:145-9. Epub 2013/01/26.
Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-19.
Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. The Journal of asthma: Official Journal of the Association for the Care of Asthma 2014;51:669-76.
Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine 2013;19:977-9. Epub 2013/08/08.
Carr TF, Zeki AA, Kraft M. Eosinophilic and Noneosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine 2018;197:22-37. Epub 2017/09/15.
Irvin C, Zafar I, Good J, et al. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. The Journal of Allergy and Clinical Immunology 2014;134:1175-86 e7.
Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. The Journal of Allergy and Clinical Immunology 2004;114:1265-73; quiz 74.
Bartminski G, Crossley M, Turcanu V. Novel biomarkers for asthma stratification and personalized therapy. Expert Rev Mol Diagn 2015;15:415-30. Epub 2014/12/06.
Liang Z, Liu L, Zhao H, et al. A Systemic inflammatory endotype of asthma with more severe disease identified by unbiased clustering of the serum cytokine profile. Medicine 2016;95(25):e3774.
Heck S, Nguyen J, Le DD, Bals R, Dinh QT. Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals International Archives of Allergy and Immunology 2015;168:241-52.
Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. American Journal of Respiratory and Critical Care Medicine 2009;180:388-95. Epub 2009/06/02.
Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. The Journal of Allergy and Clinical Immunology 2012;130:647-54 e10. Epub 2012/08/04.
Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008;38:936-46. Epub 2008/04/04.
Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. American Journal of Respiratory and Critical Care Medicine 2005;172:453-9. Epub 2005/05/20.
Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE (NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115-20.
Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Annals of the American Thoracic Society 2013;10(Suppl):S206-13.
Westerhof GA, Korevaar DA, Amelink M, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. The European Respiratory Journal 2015;46:688-96. Epub 2015/06/27.
Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. The Lancet Respiratory Medicine 2015;3:849-58. Epub 2015/10/24.
Baos S, Calzada D, Cremades-Jimeno L, et al. Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples. Frontiers in Immunology 2018;9:1416. Epub 2018/07/07.
Bellanti JA. Cytokines and allergic diseases: clinical aspects. Allergy and Asthma Proceedings 1998;19:337-41.
Mirchandani AS, Besnard AG, Yip E, et al. Type 2 innate lymphoid cells drive CD4+ Th2 cell responses. Journal of Immunology 2014;192:2442-8.
Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282(5397):2258-61.
Beghe B, Barton S, Rorke S, et al. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin Exp Allergy 2003;33:1111-7.
Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. American Journal of Respiratory and Critical Care Medicine 1994;150:1038-48. Epub 1994/10/01.
Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. American Journal of Respiratory and Critical Care Medicine 1996;154:1497-504. Epub 1996/11/01.
Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995;12:477-87. Epub 1995/05/01.
Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. Journal of Immunology 1997;158:3539-44. Epub 1997/04/01.
Shahid SK, Kharitonov SA, Wilson NM, Bush A, Barnes PJ. Increased interleukin-4 and decreased interferon-gamma in exhaled breath condensate of children with asthma. American Journal of Respiratory and Critical Care Medicine 2002;165:1290- 3. Epub 2002/05/07.
Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. The Journal of Allergy and Clinical Immunology 1997;99:657-65. Epub 1997/05/01.
Kotsimbos TC, Ernst P, Hamid QA. Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians 1996;108:368-73. Epub 1996/09/01.
Komai-Koma M, McKay A, Thomson L, et al. Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy. 2001;31:1441-8. Epub 2001/10/10.
Tang L, Lin HG, Chen BF. Association of IL-4 promoter polymorphisms with asthma: a meta-analysis. Genetics and Molecular Research: GMR 2014;13:1383-94.
Heinzmann A, Mao XQ, Akaiwa M, et al. Genetic variants of IL-13 signalling and human asthma and atopy. Human Molecular Genetics 2000;9:549-59.
Nie W, Liu Y, Bian J, Li B, Xiu Q. Effects of polymorphisms -1112C/T and +2044A/G in interleukin-13 gene on asthma risk: a meta-analysis. PloS one 2013;8:e56065.
Wang ZD, Lian D, Shen JL, et al. Association between the interleukin-4, interleukin-13 polymorphisms and asthma: a meta-analysis. Molecular Biology Reports 2013;40:1365-76.
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98. Epub 2011/08/05.
Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology 2016;170:122-31. Epub 2016/09/17.
Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. The Journal of Allergy and Clinical Immunology 2000;105(6 Pt 1):1063-70.
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus. a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388(10039):31-44. Epub 2016/05/01.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018;378:2475-85. Epub 2018/05/22.
Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018;378:2486-96. Epub 2018/05/22.
Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. The Journal of Allergy and Clinical Immunology 2016;137:75-86 e8.
Wood LJ, Sehmi R, Dorman S, et al. Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. American Journal of Respiratory and Critical Care Medicine 2002;166:883-9.
Dorman SC, Efthimiadis A, Babirad I, et al. Sputum CD34+IL5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis. American Journal of Respiratory and Critical Care Medicine 2004;169:573-7.
Park SW, Kim DJ, Chang HS, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. International Archives of Allergy and Immunology 2003;131:283-90.
Kabesch M, Depner M, Dahmen I, et al. Polymorphisms in eosinophil pathway genes, asthma and atopy. Allergy 2007;62:423-8.
Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012;42:712-37.
Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Current Opinion in Allergy and Clinical Immunology 2016;16:186-200.
Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Design, Development and Therapy 2018;12:619-28.
Pelaia G, Vatrella A, Busceti MT, et al. Role of biologics in severe eosinophilic asthma - focus on reslizumab. Therapeutics and Clinical Risk Management 2016;12:1075-82.
Matera MG, Calzetta L, Rinaldi B, Cazzola M. Pharmacokinetic/ pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert opinion on drug metabolism & toxicology. 2017;13:1007-13.
Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International 2018;2018:4839230. Epub 2018/06/05.
Al-Ramli W, Prefontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. The Journal of Allergy and Clinical Immunology 2009;123:1185-7.
Chesne J, Braza F, Mahay G, Brouard S, Aronica M, Magnan A. IL-17 in severe asthma. Where do we stand? American Journal of Respiratory and Critical Care Medicine 2014;190:1094-101. Epub 2014/08/28.
Vittal R, Fan L, Greenspan DS, et al. IL-17 induces type V collagen overexpression and EMT via TGF-beta-dependent pathways in obliterative bronchiolitis. American journal of physiology Lung Cellular and Molecular Physiology 2013;304:L401-14. Epub 2012/12/25.
Ji X, Li J, Xu L, et al. IL4 and IL-17A provide a Th2/Th17-polarized inflammatory milieu in favor of TGF-beta1 to induce bronchial epithelial-mesenchymal transition (EMT). International Journal of Clinical and Experimental Pathology 2013;6:1481-92. Epub 2013/08/08.
Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respiratory Medicine 2010;104:1131-7.
Linden A, Dahlen B. Interleukin-17 cytokine signalling in patients with asthma. The European Respiratory Journal 2014;44:1319- 31.
Ciprandi G, Cuppari C, Salpietro AM, et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. International Archives of Allergy and Immunology 2012;159:183-6.
Fattahi F, Brandsma CA, Lodewijk M, et al. Atopy and Inhaled Corticosteroid Use Associate with Fewer IL-17+ Cells in Asthmatic Airways. PloS one 2016;11:e0161433.
Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN. Allergic sensitization through the airway primes Th17- dependent neutrophilia and airway hyperresponsiveness. American journal of Respiratory and Critical Care Medicine 2009;180:720-30.
Wakashin H, Hirose K, Maezawa Y, et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. American journal of Respiratory and Critical Care Medicine 2008;178:1023-32.
Bajoriuniene I, Malakauskas K, Lavinskiene S, et al. Response of peripheral blood Th17 cells to inhaled Dermatophagoides pteronyssinus in patients with allergic rhinitis and asthma. Lung 2012;190:487-95.
Camargo LDN, Righetti RF, Aristoteles L, et al. Effects of AntiIL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS. Frontiers in Immunology 2017;8:1835. Epub 2018/01/31.
Zhu M, Wang T, Chen R, Wang C, Liu S, Ji Y. Association between interleukin-17a gene polymorphisms and asthma risk: a metaanalysis. Asian Pacific Journal of Allergy and Immunology 2016;34:115-23.
Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. American journal of Respiratory and Critical Care Medicine 2013;188:1294-302. Epub 2013/11/10.
Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383(6603):787-93.
Cosmi L, Maggi L, Santarlasci V, et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. The Journal of Allergy and Clinical Immunology 2010;125:222-30 e1-4.
Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009;30:646-55.
O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327(5969):1098-102.
Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nature immunology 2010;11:674-80.
Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity 2009;31:859-71.
Locksley RM. Nine lives: plasticity among T helper cell subsets. The Journal of Experimental Medicine 2009;206:1643-6.
Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proceedings of the American Thoracic Society 2009;6:256-9.
Choy DF, Hart KM, Borthwick LA, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Science Translational Medicine 2015;7(301):301ra129. Epub 2015/08/21.
Journals System - logo
Scroll to top